Alkermes Plc (ALKS)
49.26
+0.39
(+0.80%)
USD |
NASDAQ |
Aug 25, 11:23
Alkermes Price to Book Value : 4.563 for Aug. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 4.527 |
| August 21, 2026 | 4.477 |
| August 20, 2026 | 4.448 |
| August 19, 2026 | 4.649 |
| August 18, 2026 | 4.584 |
| August 17, 2026 | 4.618 |
| August 14, 2026 | 4.545 |
| August 13, 2026 | 4.581 |
| August 12, 2026 | 4.658 |
| August 11, 2026 | 4.559 |
| August 10, 2026 | 4.576 |
| August 07, 2026 | 4.555 |
| August 06, 2026 | 4.481 |
| August 05, 2026 | 4.596 |
| August 04, 2026 | 4.601 |
| August 03, 2026 | 4.588 |
| July 31, 2026 | 4.538 |
| July 30, 2026 | 4.635 |
| July 29, 2026 | 4.478 |
| July 28, 2026 | 4.678 |
| July 27, 2026 | 4.885 |
| July 24, 2026 | 4.900 |
| July 23, 2026 | 4.907 |
| July 22, 2026 | 4.871 |
| July 21, 2026 | 4.896 |
| Date | Value |
|---|---|
| July 20, 2026 | 4.791 |
| July 17, 2026 | 4.884 |
| July 16, 2026 | 4.812 |
| July 15, 2026 | 4.815 |
| July 14, 2026 | 4.780 |
| July 13, 2026 | 4.805 |
| July 10, 2026 | 4.812 |
| July 09, 2026 | 4.982 |
| July 08, 2026 | 5.029 |
| July 07, 2026 | 5.116 |
| July 06, 2026 | 5.108 |
| July 02, 2026 | 5.056 |
| July 01, 2026 | 4.791 |
| June 30, 2026 | 4.854 |
| June 29, 2026 | 4.992 |
| June 26, 2026 | 5.235 |
| June 25, 2026 | 5.021 |
| June 24, 2026 | 4.795 |
| June 23, 2026 | 4.568 |
| June 22, 2026 | 4.374 |
| June 18, 2026 | 4.276 |
| June 17, 2026 | 4.230 |
| June 16, 2026 | 4.190 |
| June 15, 2026 | 4.216 |
| June 12, 2026 | 4.208 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amarin Corp. Plc | 0.6604 |
| Jazz Pharmaceuticals Plc | 3.558 |
| Prothena Corp. Plc | 1.728 |
| ACADIA Pharmaceuticals, Inc. | 4.004 |
| Biogen, Inc. | 1.738 |
Price to Book Value Related Metrics
| PE Ratio | 127.95 |
| PS Ratio | 5.005 |
| Price to Free Cash Flow | 37.65 |
| Price | 49.26 |
| Earnings Yield | 0.78% |
| Market Cap | 8.253B |
| Operating PE Ratio | 58.09 |
| Normalized PE Ratio | 100.20 |